Cancer Risk in Individuals Who Have a Xeroderma Pigmentosum Gene Alteration Compared With Those Who Don't
Status: | Archived |
---|---|
Conditions: | Cancer, Dermatology |
Therapuetic Areas: | Dermatology / Plastic Surgery, Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Cancer Risk In Xeroderma Pigmentosum Heterozygotes
RATIONALE: Screening individuals who have a xeroderma pigmentosum gene alteration may help
doctors identify persons at risk of developing cancer and identify other cancer genes.
PURPOSE: This clinical trial is comparing cancer risk in individuals who have a xeroderma
pigmentosum gene alteration to those who don't.
OBJECTIVES:
- Compare risk of developing any type of cancer in participants who are heterozygous
carriers of xeroderma pigmentosum (XP) disease gene mutations vs non-carrier blood
relatives or spouses.
- Compare risk of developing skin cancers or cancers of the nervous system in these
participants.
- Compare cancer risk in different groups among heterozygous carriers of XP disease gene
mutations.
- Compare cancer risk in carriers of different XP disease gene mutations with
heterozygous carriers of these gene mutations.
OUTLINE: Participants undergo general cancer screening comprising a medical history and
physical examination, including a skin and neurologic examination. Laboratory samples are
collected for review.
Participants are followed annually by telephone or mail to determine clinical status.
PROJECTED ACCRUAL: Approximately 800 participants (400 heterozygous carriers and 400
non-carrier blood relatives or spouses) will be accrued for this study.
We found this trial at
1
site
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
Click here to add this to my saved trials